-
Presentation of Medistim’s Q4 and preliminary year-end results 2022
The financials will be presented via a live webinar on Wednesday, March 1st from 08:00-09:00 (CET). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available…
Read more -
Medistim celebrates a long-standing relationship with the Japanese cardiac surgery community
“This is very much a story of a perfect fit between Norwegian technology and Japanese quality standards. Medistim technology has been able to meet expectations of the quality driven Japanese market. There are few arenas…
Read more -
Results for the third quarter 2022
In the third quarter, total revenue ended at MNOK 116.5 (MNOK 102.1), a 14.0% increase. Sales growth is driven by the USA with a currency-neutral sales increase of 18.7 % for the quarter and 24.1…
Read more -
New ESVS Guidelines recommend intraoperative ultrasound after CEA
The Guidelines are set to identify luminal thrombus after flow restoration, diagnose intimal flaps and diagnose residual stenoses during surgery. The new recommendation is based on a meta-analysis by Knappich et al. 20212 that shows…
Read more -
Results for the second quarter and first half 2022
Sales growth is driven by the USA with a currency-neutral sales increase of 28 % for the quarter and 29 % for the first half. Strategic areas of Vascular Surgery and Imaging products show high…
Read more -
Results for the First Quarter 2022
All-time high sales for a quarter ending at MNOK 116.1 (MNOK 102.6), an increase of 13.2%. Sales growth is driven by the USA with a currency-neutral increase of 34.2%. Currency neutral sales of own products…
Read more -
Kari E. Krogstad winner of the Arthur D. Little Nordic Life Science Award 2021
The prize was awarded at a ceremony in Stockholm on April 4, 2022. The Arthur D. Little Nordic Life Science Award is given to a person in the Nordic region that has demonstrated outstanding management…
Read more -
Annual Report 2021
This rebound has continued throughout 2021, and Medistim has experienced strong growth in revenues due to the increase in number of CABG procedures performed. The sales growth was 17.6 % in NOK and operating profit…
Read more -
Results for the Fourth Quarter and Preliminary Results for 2021
All time high sales for a quarter, ending at MNOK 112.7 (MNOK 94.2), an increase of 19.7%. Full year 2021 sales ended at a record of MNOK 427.3 (MNOK 363.1). Currency neutral sales of own…
Read more -
Results for the Third Quarter 2021
Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9…
Read more